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A B S T R A C T
Objective: Is treatment of early pregnancy failure (EPF) with sequential use of mifepristone and
misoprostol more effective than treatment with misoprostol alone?
Study design: In a retrospective cohort study at the Department of Obstetrics and Gynaecology of the
Radboud University Medical Centre, 301 women with early pregnancy failure receiving medical
treatment between January 2008 and March 2013 were included. Of these, 199 women were pre-treated
with 200 mg mifepristone (orally) followed by 2 consecutive doses of 800 mcg misoprostol (vaginally)
and 102 women were treated with 2 consecutive doses of 800 mcg misoprostol (vaginally) alone.
Results: Complete expulsion was achieved in 66.8% of the women treated with a sequential combination
of mifepristone and misoprostol versus 54.9% of the women treated with misoprostol alone. The
difference in rates of complete expulsion was 11.9% (P < 0.05; 95% CI 0.3–23.6%).
Conclusions: Medical treatment of early pregnancy failure with a sequential combination of
mifepristone and misoprostol was more effective than treatment with misoprostol alone. Our ﬁndings
will have to be conﬁrmed by a large prospective multicentre double blinded-randomized trial.
 2014 Elsevier Ireland Ltd. All rights reserved.
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Early pregnancy failure (EPF) is a common complication of
pregnancy, as 10% to 20% of all clinically recognized pregnancies
will end in EPF [1]. For many years surgical evacuation was the
standard treatment, but more recently medical management has
gained a substantial role in treatment of EPF. Medical management
of EPF with the prostaglandin E1 analogue misoprostol has been
the subject of many studies showing complete expulsion rates
using between 53% and 87% [2–5]. As evidence is growing that
surgical management may have major long-term consequences,
such as intra-uterine adhesions and increased spontaneous
preterm birth rates in subsequent pregnancies, the potential of
successful medical treatment of EPF is of utmost importance [6,7].* Corresponding author. Tel.: +31 6 266 464 84; fax: +31 24 365 8245.
E-mail addresses: j.vandenberg@cwz.nl, joycie.vdberg@gmail.com
(J. van den Berg).
http://dx.doi.org/10.1016/j.ejogrb.2014.10.010
0301-2115/ 2014 Elsevier Ireland Ltd. All rights reserved.Mifepristone is an anti-progesterone and anti-glucocorticoid
drug and is registered for induction of abortion in viable
pregnancies up to a gestational age of 63 days [8]. The sequential
combination of mifepristone (200 mg) with misoprostol (800 mcg)
has been shown superior to the use of misoprostol alone (800 mcg)
for medical termination of viable pregnancies [9]. The rate of
complete abortion after treatment with a combination of
mifepristone and misoprostol is reported to be as high as 95% [10].
Several studies examined the combination of mifepristone and
misoprostol in cases of EPF and found it an effective and safe
alternative to surgical treatment, with success rates ranging
between 65.5% and 93% [11–15]. Unfortunately, these studies had
limitations due to study design, small sample size and heteroge-
neous inclusion criteria. Therefore, conﬂicting ﬁndings about the
value of mifepristone need to be resolved by additional studies
[3]. In preparation for this trial we conducted a retrospective study
to compare complete expulsion rates with a combination of
mifepristone and misoprostol versus misoprostol alone in women
with early pregnancy failure.
Table 1
Baseline characteristics.
Misoprostol
(N = 102)
Mifepristone and
misoprostol (N = 199)
P value
Age (years), mean 32.6 33.0 0.44
SD 4.5 4.9
Anembryonic gestation 28 (27.5%) 54 (27.1%) 1.00
Embryonic/fetal demise 74 (72.5%) 145 (72.9%)
Gestational age amenorrhea
(days), mean
71.8 74.1 0.08
SD 9.8 10.1
Ultrasound gestational age
(days), mean
53.0 52.9 0.99
SD 9.8 10.2
Nulliparous 39 (38.2%) 81 (40.7%) 0.62
Previous miscarriage 40 (39.2%) 60 (30.2%) 0.15
Previous elective
abortion (APLA)
13 (12.7%) 26 (13.1%) 1.00
Previous caesarean section 6 (5.9%) 27 (13.6%) 0.06
No statistically
signiﬁcant differences
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We performed a single-centre retrospective cohort study of
women treated in the Radboud University Medical Centre between
January 2008 and March 2013, to study the effectiveness of
mifepristone in women treated for early pregnancy failure. Ethics
approval was not required for this study; this was conﬁrmed by our
local medical ethics committee.
Patient selection
Mifepristone (Mifegyne1, Exelgyn France, Nordic Pharma, The
Netherlands) is registered for induction of abortion in the
Netherlands. It is solely available in clinics authorized by an explicit
jurisdictional approval of the Minister of Health. Therefore a strict
registration of distributed mifepristone is used in the outpatient
clinic. This registration was used to identify women treated with
mifepristone between April 2010 and March 2013. The use of
misoprostol (Cytotec1, Pﬁzer The Netherlands) for the indication EPF
is ‘‘off label’’ and also registered. To search for patients potentially
not listed in these registrations, electronic patient records were
searched between January 2008 and March 2010 for variables such
as absent fetal heartbeat and gestational age less than 14 weeks.
Inclusion criteria for this cohort study were the presence of a
non-viable pregnancy before 14 weeks’ gestation and an indication
for medical treatment. A non-viable pregnancy was deﬁned either
as an anembryonic gestation with a blighted ovum or as early
embryonic/fetal demise showing an embryo without cardiac
activity. In The Netherlands, expectant management for at least
one week after the diagnosis has been established is common
practice, because spontaneous complete expulsion rates of 50% are
to be expected during this ﬁrst week [16].
Exclusion criteria were imminent miscarriage (products of
conception passing through the cervical os at presentation at the
outpatient department) and incomplete miscarriage, which was
deﬁned as retained products of conception (endometrial lining
>15 mm) after expulsion of an intrauterine pregnancy.
Treatment protocols
At our clinic, women with early pregnancy failure are counseled
according to a local protocol with respect to three options:
expectant management, or medical or surgical treatment. Before
April 2010 medical treatment of EPF consisted solely of adminis-
tration of two consecutive doses of misoprostol 800 mcg vaginally
(time interval of 24 h) without mifepristone. Thereafter, medical
treatment consisted of 200 mg mifepristone orally followed by
800 mcg misoprostol vaginally 36 h later administered at home.
When cramps or vaginal bleeding do not occur within 24 h after
the ﬁrst dosage of misoprostol, women are instructed to use
another dosage of 800 mcg misoprostol vaginally the next day.
Outcome measures
The primary outcome parameter was complete expulsion,
deﬁned as asymptomatic women after clinical signs of a complete
miscarriage, or an empty uterine cavity seen on vaginal ultrasound,
or an empty uterine cavity seen during hysteroscopy, or a histology
report after surgical evacuation describing the absence of the
products of conception. The study outcome was determined at
different time points depending on the policy of the treating
physician. Secondary outcome parameters were the different
reasons for failure of treatment (no expulsion of products,
persistent gestational sac, suspected residue, excessive blood loss
or suspected infected residue) and factors that could affect the rate
of complete expulsion like gestational age and parity.Statistical analyses
SPSS version 20.0 was used for data analysis. Differences
between groups were analyzed using Pearson’s chi-square test or
Fisher’s exact test for categorical variables. The Mann–Whitney U
test was used for non-normally distributed metric variables.
Logistic regression analysis was performed to identify factors that
were associated with treatment success. P values smaller than
0.05 were considered signiﬁcant.
Results
Baseline characteristics were not signiﬁcantly different be-
tween the treatment groups (Table 1). A total of 311 women were
medically treated for early pregnancy failure at the Radboud
University Medical Centre in the period between January 2008 and
March 2013. Ten cases were excluded because there were no exact
data on the primary outcome. A total of 102 women were treated
with misoprostol alone and 199 women were treated with the
sequential combination of mifepristone and misoprostol.
Complete expulsion (Table 2) was achieved in 66.8% of the
women treated with a sequential combination of mifepristone and
misoprostol compared to 54.9% of the women treated with
misoprostol alone. The difference in rates of complete expulsion
was 11.9% (P < 0.05; 95% CI 0.3%–23.6%). In women diagnosed with
an anembryonic gestation (AG) the rate of complete miscarriage
did not differ signiﬁcantly between the two treatment groups. In
women diagnosed with embryonic/fetal demise (EFD) the rate of
complete expulsion after treatment with a sequential combination
of mifepristone and misoprostol was 64.1%, compared to 44.1% in
women treated with misoprostol alone (P < 0.01, difference 20%,
95%CI: 5.8%–33.3%).
In 113 women who needed a surgical intervention after medical
treatment, two were diagnosed with an empty uterine cavity
during hysteroscopy. Hysteroscopy was performed in women
presenting more than six weeks after medical treatment with a
suspicion of retained products of gestation. In three women treated
with dilatation and curettage the pathologist reported absence of
gestational products.
Table 3 shows indications for surgical management after failed
medical treatment. Most women were surgically treated due to a
suspicion of retained products of gestation. In women treated with
misoprostol alone 30% of the indications for surgical intervention
were because of a persistent gestational sac, compared to 9% in the
group treated with a sequential combination of mifepristone and
misoprostol (difference 21%, P < 0.01, 95%CI: 6.6%–35.5%). Ten
Table 2
Outcome measures of consecutive combination of mifepristone and misoprostol
versus misoprostol alone.
Misoprostol,
% (n/N)
Mifepristone
and misoprostol,
% (n/N)
P value
Complete expulsion
rate (total)
54.9 (56/102) 66.8 (133/199) <0.05
Complete expulsion
rate (AG)
75.0 (21/28) 74.1 (40/54) 1.00
Complete expulsion
rate (EFD)
44.6 (33/74) 64.1 (93/145) <0.01
AG = Anembryonic
gestation, EFD = Embryonic
or fetal demise
40
45
50
55
60
65
70
75
80
85
≤7 weeks 
n=1 0
8 weeks
n=33
9 weeks
n=52
10 weeks
n=99
11 weeks
n=55
12 wee ks
n=31
13 wee ks
n=19
Pe
rc
en
ta
ge
Amenorrhea 
Fig. 1. Complete expulsion rate.
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misoprostol had a surgical intervention because of excessive
bleeding. Among the patients treated with misoprostol alone, one
patient needed an intervention due to hemorrhage.
After adjusting for gestational age a non-signiﬁcant declining
rate of complete expulsion was observed, as shown in Fig. 1
(P = 0.06). No differences in primary outcome were observed after
adjusting for the difference between time since last menstrual
period and ultrasound gestational age, parity, prior miscarriages,
prior elective abortions or prior dilatation and curettage.
Comment
Main ﬁndings
This retrospective study compared rates of complete expulsion
of EPF after medical treatment with sequential mifepristone and
misoprostol to those after treatment with misoprostol alone after
at least one week of expectant management. Sequential treatment
with mifepristone and misoprostol resulted in a 66.8% complete
expulsion rate and treatment with misoprostol alone resulted in a
54.9% complete expulsion rate. The difference in rates of complete
expulsion was statistically signiﬁcant.
Strengths and limitations
EPF is a common complication of pregnancy, and therefore we
were able to include a large group of women. Our baseline data
showed no signiﬁcant difference between the two treatment
groups. Diagnosis of early pregnancy failure, therapy counseling
and patient information was standardized. A uniform treatment
protocol was available and there was a clear and objective outcome
deﬁnition.
A limitation of our ﬁndings is the retrospective study design.
The data were collected directly from patient charts, which could
be inconclusive or incomplete. The allocation to the two treatment
groups was caused by a protocol change in April 2010, but a
minority of women were still treated according to the old protocol
after 2010.Table 3
Indications for surgical intervention after failed medical treatment.
Misoprostol,
% (n/N)
Mifepristone
and misoprostol,
% (n/N)
P value
Surgical intervention (total) 49.0 (50/102) 33.7 (67/199) <0.05
Suspected residua 62.0 (31/50) 65.7 (44/67) 0.70
Persistent gestational sac 30.0 (15/50) 9.0 (6/67) <0.01
Suspected residua
with signs of infection
6.0 (3/50) 7.5 (5/67) 1.00
Hemorrhage 2.0 (1/50) 14.9 (10/67) <0.05Interpretation
Success rates of the use of misoprostol alone vary from 53% to
88% [2,5,14,17–20]. These studies are heterogeneous in their
deﬁnition of complete abortion, duration of follow-up period and
doses of misoprostol [11–13,21,22]. As an example, in the studies
of Wagaarachchi et al. up to 1600 mcg misoprostol for two
consecutive days was given [21,22]. Others used different
frequencies of administration such as two consecutive doses of
800 mcg misoprostol followed by an additional dose after one
week if necessary [20]. Regarding follow-up, Kollitz and Petersen
used an endometrial lining of <30 mm to diagnose complete
miscarriage after one week [5,12]. In essence, there is no consensus
on the diagnosis of a complete miscarriage. Some clinicians or
researchers use clinical symptoms like the cessation of vaginal
blood loss and cramps. Others use ultrasonographic criteria such as
the absence of a gestational sac or an endometrial lining of less
than 15 or 30 mm. Some data show that there is no relationship
between increasing endometrial residue-thickness and the need
for surgical intervention in women treated with misoprostol for
early pregnancy failure [23,24]. In our centre, clinicians use a
maximum endometrial lining of 15 mm with absence of vaginal
bleeding to diagnose complete miscarriage one week after
treatment. This may have led to a lower success rate of treatment
compared to other studies using less stringent criteria for complete
miscarriage. We are eagerly awaiting the results of the Dutch
‘‘Misorest’’ study, ultimately deﬁning the effectiveness of expec-
tant management and curettage in symptom-free women with
sonographic evidence of incomplete evacuation of a miscarriage
after misoprostol treatment.
Graziosi et al. found a success rate of misoprostol after one week
of expectant management of 53.2%, comparable with 54.9% found
in our study. Graziosi concluded that these lower success rates
might be due to this patient selection after one week of expectant
management [2]. Indeed, Torre et al. conducted a randomized trial
to compare delayed treatment with direct medical treatment and
concluded that delayed treatment is less effective than direct
treatment [25]. In women treated with mifepristone and
misoprostol we found a 66.8% rate of complete expulsion after
one week expectant management, which is comparable with the
percentage success found by several other studies (66–74%)
[14,15,26].
Additional ﬁndings
The difference in expulsion rates between the two treatment
regimens in women with an anembryonic gestation (AG) and
women having an early embryonic/fetal demise (EFD) has not been
described in earlier studies. Wagaarachchi et al. described the two
groups separately but found no signiﬁcant difference in treatment
success [21]. Kollitz et al. described a difference between AG and
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compared to 88% in the group of women with EFD [12]. The data of
Zhang et al. showed that the success rate of treatment of AG was
lower compared to the success rate of treatment of women having
an EFD [4].
Practical and research recommendations
Reﬂecting on cost-effectiveness, it may already be clear that
medical treatment delivered at an outpatient department, with the
intention of spontaneous miscarriage at home, will decrease costs
substantially compared to clinical surgical treatment. Besides, since
the patent on mifepristone has expired, the costs of mifepristone are
already decreasing drastically. Because of the decreasing costs of
mifepristone, even a small increase in the rate of complete expulsion
may lead to a decrease in overall treatment costs.
Based on the results of our study, treatment of early pregnancy
failure with the sequential combination of mifepristone and
misoprostol appears to be more effective than misoprostol alone. A
randomized, double blind placebo-controlled trial is urgently
needed. Such a trial could conﬁrm that treatment with mifepris-
tone and misoprostol may lead to higher complete evacuation
rates and thus a signiﬁcant reduction of costs.
Conclusion
In our retrospective study, treatment of early pregnancy failure
with a sequential combination of mifepristone and misoprostol
was signiﬁcantly more effective than treatment with misoprostol
alone. These ﬁndings should be conﬁrmed by a multicentre double
blinded-randomized trial.
Condensation
Medical treatment of early pregnancy failure with a sequential
combination of mifepristone and misoprostol appears more
effective than treatment with misoprostol alone.
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